Zenith Drugs Ltd – Company Report
1. Company Overview
Zenith Drugs Ltd, established in 2000 and headquartered in Indore, Madhya Pradesh, is a respected pharmaceutical manufacturer and trader with a robust presence in both domestic and global markets. The company specializes in the development, production, and export of branded, generic, and over-the-counter (OTC) pharmaceutical products, with a portfolio covering more than 600 formulations. Zenith’s capabilities span oral solids and liquids, ointments, capsules, creams, gels, and solutions manufactured in a WHO-GMP and ISO 9001:2015 certified facility. The company’s integrated business model and comprehensive R&D allow it to serve the healthcare needs of 18+ Indian states and more than 25 countries across Africa, Southeast Asia, Latin America, and the CIS region.
Key Highlights:
- Incorporated: 2000
- Headquarters: Indore, Madhya Pradesh, India
- Certifications: WHO-GMP, ISO 9001:2015, Schedule M GMP, multiple regulatory approvals
- Employees: 200–500
- Manufacturing: Over 250 molecules and 780 SKUs, with new facilities under development
- Market Reach: Presence in 18 Indian states and 25+ export destinations
- Product Range: ORS powder, oral and external liquids, ointments, gels, creams, tablets, capsules
2. Products and Services
- Extensive Portfolio: ORS powders, tablets, dry powder syrups, oral liquids, ointments, gels, creams, capsules, solutions, and injectables (under expansion)
- Therapeutic Segments: Allergology, infection, endocrinology, microbiology, genetics, and general analytics
- R&D and Formulation: In-house team dedicated to continuous product innovation, stability studies, and quality improvement
- Private Label/Third-Party Manufacturing: Flexible manufacturing for leading pharma brands, health organizations, and institutional contracts
- Export Division: Regulatory documentation for international markets, including US, African, and Asian regions
- Quality and Compliance: Stringent quality control and adherence to ICH and WHO-GMP standards
3. Recent News and Business Developments
Government Recognition: Named among the top 10 MSME pharmaceutical manufacturers in Indore, awarded major government tenders in FY2025
Product Launches: Introduced new lines in dermatology, paediatrics, and nutraceuticals, enhancing domestic penetration
November 10, 2025: Awarded a supply tender by Uttar Pradesh Medical Supplies Corporation Limited (UPMSCL). The order is for Clobetasol Propionate Cream 0.05% w/w (15 gm, 1,20,000 units), Indomethacin Capsules 25 mg (1×10 per strip, 59,34,720 units), and Tramadol Hydrochloride Capsules 50 mg (1×10 per strip, 90,31,760 units).
October 16, 2025: A Woman reported black worm-like particles in Azithromycin syrup at a Gwalior hospital. Authorities recalled 306 bottles, halted distribution, and sent samples for testing. The generic medicine, made by Zenith Drugs Ltd., is under investigation, with strict legal action promised if found substandard.
August 22, 2024: Zenith Drugs Ltd. announced the completion of construction of its new manufacturing plant at Village Muradpura, Depalpur, Indore. Beginning September 2024, the facility will commence manufacturing tablet and liquid oral formulations.
Growth Strategy:
- Doubling Production Capacity through backward integration
- Expanding dosage forms and regulatory filings for entry into regulated markets
- Strategic expansion supports Zenith’s vision of becoming a key mid-sized pharmaceutical exporter
4. Financial Performance (FY2025)
| Metric | FY2025 Value |
|---|---|
| Total Revenue | ₹135 crore |
| Net Profit | ₹7.4 crore |
| EPS | ₹4.18 |
| Net Profit Margin | 5.5% |
| Return on Equity (ROE) | 11% |